Table 1. Abnormal Serologies, Proteinuria and Serum Creatinine in the Patient of This Report .
| Laboratory value | Normal Range | 1st Period | 2nd Period | 3rd Period | 4th Period |
|---|---|---|---|---|---|
| Serum ANA titer | < 1:40 | > 1:2,560 | > 1:2,560 | ≥ 1:2,560 | ≥ 1:2,560 |
| Serum Anti-U1-RNP titer | < 1:40 | > 1:512 | > 1:512 | > 1:512 | > 1:512 |
| Serum MPO ANCA, u/L, Mean ± SD | 0 - 99 | 35.1 ± 18.6 | 789 | 317.0 ± 306.3 | 173.6 ± 91.8 |
| 95% CI | -131.9-202.2 | -170.4-804.3 | 59.6 - 287.6 | ||
| Serum C4 complement, mg/dL, Mean ± SD | 16 - 47 | 10.5 ± 1.2 | 10.0 ± 1.2 | 11.4 ± 1.7 | 17.0 ± 1.7 |
| 95% CI | 7.4 - 13.5 | 8.9 - 11.1 | 10.1 - 12.7 | 15.5 - 18.4 | |
| Serum C3 complement, mg/dL, Mean ± SD | 88 - 201 | 83.7 ± 9.1 | 108.3 ± 15.8 | 124.6 ± 12.6 | 129.3 ± 10.6 |
| 95% CI | 60.9 - 106.4 | 93.6 - 122.9 | 114.9 - 134.2 | 120.3 - 138.2 | |
| Serum CRP, mg/dL, Mean ± SD | 0 - 1 | 1.5 ± 1.0 | - | 1.0 ± 0.6 | 0.4 ± 0.2 |
| 95% CI | -0.9-3.92 | 0.1 - 2.0 | 0.1 - 0.8 | ||
| ESR, mm/hr, Mean ± SD | < 20 | 84 ± 13 | - | 40 | 24 ± 10 |
| 95% CI | -30-198 | 1 - 48 | |||
| Serum creatinine, mg/dL, Mean ± SD | 0.66 - 1.25 | 0.75 ± 0.06 | 0.99 ± 0.16 | 1.00 ± 0.20 | 0.98 ± 0.06 |
| 95% CI | 0.66 - 0.84 | 0.85 - 1.12 | 0.82 - 1.18 | 0.93 - 1.02 | |
| Urine protein/creatinine, gr/gr, Mean ± SD | < 0.1 | 1.2 ± 1.0 | 7.6 ± 2.3 | 6.4 ± 2.9 | 1.6 ± 1.0 |
| 95% CI | -0.3-2.8 | 6.1 - 9.0 | 4.5 - 8.3 | 0.9 - 2.3 |
1st Period: From the MCTD diagnosis until the development of the nephrotic syndrome (3 years); 2nd Period: Nephrotic syndrome prior to treatment (5 months); 3rd Period: Treatment with cyclophosphamide (1 year); 4th Period: Post-treatment follow-up (6 years). CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SD: standard deviation; 95% CI: 95% confidence interval. Large confidence intervals with negative lower limits were computed in periods with two or three measurements.